<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872950</url>
  </required_header>
  <id_info>
    <org_study_id>2001-040</org_study_id>
    <nct_id>NCT00872950</nct_id>
  </id_info>
  <brief_title>3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)</brief_title>
  <acronym>LEMS</acronym>
  <official_title>Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lahey Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and adverse effects of&#xD;
      3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and&#xD;
      Congenital Myasthenic Syndromes (CMS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, non-randomized, non-comparative expanded access study. Up to 25&#xD;
      patients with clinically proven paraneoplastic or primary autoimmune LEMS per EMG and&#xD;
      positive voltage-gated calcium channel antibody serology, OR patients with clinically proven&#xD;
      CMS per EMG, biopsy or genetic testing who meet the selection criteria outlined in sections&#xD;
      3.1 and 3.2 will be enrolled in this study. Subjects will receive 3,4-DAP starting with a low&#xD;
      dose and titrating up per efficacy and patient tolerance to a maximum daily dose of 100mg .&#xD;
      Treatment will continue until the subject experiences a treatment-limiting toxicity,&#xD;
      voluntarily withdraws consent, transfers to another site, dies, becomes lost to follow-up, is&#xD;
      no longer receiving clinical benefit from 3,4-DAP (in the opinion of the subject and/or the&#xD;
      investigator), or the Jacobus Pharmaceuticals or the FDA discontinues the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in strength and autonomic symptoms</measure>
    <time_frame>1-10 years</time_frame>
    <description>Patients will be monitored for strength and side effects. Treatment will be continued indefinitely if a good clinical response is achieved and side effects tolerable.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Lambert-Eaton Myasthenic Syndrome</condition>
  <condition>Congenital Myasthenic Syndrome</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3,4-DIAMINOPYRIDINE</intervention_name>
    <description>Treatment will begin with a low dose and will be increased as clinically needed as tolerated. The upper limit will be a total of 100mg/day.</description>
    <arm_group_label>Open label</arm_group_label>
    <other_name>3,4 DAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  LEMS diagnosis OR Pre or Post Synaptic CMS diagnosis&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Females must have negative pregnancy test and be willing to practice an effective form&#xD;
             of birth control&#xD;
&#xD;
          -  No prolonged QT syndrome as indicated by baseline EKG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known sensitivity to 3,4-DIAMINOPYRIDINE&#xD;
&#xD;
          -  History of seizures and/or severe asthma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayashri Srinivasan, MD,MCRP,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lahey Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lahey Hospital &amp; Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lahey.org</url>
    <description>Lahey Hospital &amp; Medical Center</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 30, 2009</study_first_submitted>
  <study_first_submitted_qc>March 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2009</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LEMS</keyword>
  <keyword>CMS</keyword>
  <keyword>3,4 DIAMINOPYRIDINE</keyword>
  <keyword>3,4 DAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
    <mesh_term>Myasthenic Syndromes, Congenital</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amifampridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

